Table 2 Propensity score-weighted cause-specific hazard ratio for composite major adverse kidney events.

From: Real-world effectiveness and safety of sodium-glucose co-transporter 2 inhibitors in chronic kidney disease

Variable

HR

95% CI

P-value

Treatment

   

SGLT2i vs. RAAS blockade

0.59

(0.36–0.98)

0.041*

Sex (Male vs. Female)

0.70

(0.52–0.95)

0.020*

Age (year)

0.95

(0.93–0.97)

< 0.001*

Comorbidities

   

Type 2 diabetic mellitus

1.36

(0.84–2.21)

0.207

Hypertension

0.94

(0.52–1.72)

0.846

Cardiovascular disease

1.73

(1.35–2.22)

< 0.001*

Peripheral vascular disease

2.41

(1.60–3.64)

< 0.001*

Medications

   

Anti-Arrhythmic

1.83

(1.25–2.67)

0.002*

Laboratory parameters

   

eGFR at enrollment

0.97

(0.95–0.98)

< 0.001*

Blood Glucose

1.00

(0.99–1.00)

0.575

  1. *P−value < 0.05.
  2. Composite major adverse kidney events included a decline in eGFR ≥40%, eGFR <15 ml/min/1.73m2, kidney replacement therapy initiation, and death from kidney or cardiovascular causes. Female is the reference category for comparisons.
  3. Abbreviations: CI, confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio; KRT, kidney replacement therapy; RAAS blockade, renin−angiotensin−aldosterone blockade; SGLT2i, sodium−glucose cotransporter−2 inhibitors.
Back to article page